Mankind Pharma acquires Bharat Serums and Vaccines from Advent International for Rs 13,630 crore
Mumbai/IBNS: Mankind Pharma Ltd, India’s fourth largest pharmaceutical company by market share, on Thursday (July 25) said it has entered into a definitive agreement to acquire a 100 percent stake in Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of Rs 13,630 crore, according to reports.
BSV, a branded specialty pharma platform in women’s health and critical care, reported revenues of Rs 1,723 crore in FY24, delivering robust 20 percent year-on-year growth with adjusted EBITDA margins of 28 percent.
The business has grown at a 21 percent revenue compound annual growth rate over the last three years, reports Business Standard.
According to reports, over 2,500 employees of BSV will be joining Mankind Pharma Ltd.
Earlier in February 2020, American global private equity firm Advent International Corporation acquired a 74 percent stake in BSV, providing a complete exit to private equity investors OrbiMed Asia and Kotak PE and a partial exit to the promoter Daftary family, as per reports.
Advent International, following approval from the Department of Pharmaceuticals (DoP), acquired the remaining 26 percent stake from the Daftary family in 2023-24.
The Business Standard reported, quoting Shweta Jalan, managing partner and head of Advent India, that Mankind Pharma’s investment in BSV is a testament to their approach of identifying and nurturing unique businesses, working with high-quality management teams and building these businesses into respected industry leaders.
The FY24 sales of Mankind Pharma Ltd. stood at Rs 10,335 crore, with Ebitda at Rs 2,550 crore translating into Ebitda margins of 24.7 percent.
According to a report by Mint, the acquisition of BSV will mean expansion of Mankind Pharma's brand portfolio that will now contain more than 40 brands valued at more than Rs 50 crore.
IBNS
Senior Staff Reporter at Northeast Herald, covering news from Tripura and Northeast India.
Related Articles
CRR cut, AI ethics push, and SORR benchmark: Experts hail RBI’s pragmatic policy moves
Mumbai: The Reserve Bank of India (RBI) has kept the repo rate unchanged at 6.5% while the cash reserve ratio (CRR) has been slashed by 50 basis points to 4 percent, media reports said.
JP Morgan gives 'overweight' rating to Adani Group bonds
Mumbai: US investment bank JP Morgan has assigned an 'overweight' rating to four bonds issued by the Adani Group, citing the group's capacity to scale and grow through internal cash flows, which reduces the likelihood of credit stress.
LG Electronics files DRPH with SEBI; IPO size expected to be over RS 15,000 cr
Mumbai: South Korean electronics giant LG Electronics has filed a draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on Friday for the proposed public listing of its Indian business, according to a notification on the Bombay Stock Exchange (BSE).
De-dollarisation not on India's agenda; derisking domestic trade is: RBI Governor Shaktikanta Das
Mumbai: India has not initiated any steps towards de-dollarisation and is solely focused on mitigating risks to domestic trade from geopolitical uncertainties, Reserve Bank of India (RBI) Governor Shaktikanta Das clarified on Friday, media reports said.
Latest News
FTA with EFTA nations to come into effect from October 1, says Indian Minister Piyush Goyal
Three die during protests over alleged gangrape of tribal girl in Bangladesh
Cocktail 2: Homi Adajania, Kriti Sanon join Shahid-Rashmika's pool party in Sicily, fresh picture from shoot arrives
Tension flares up in PoK as thousands come out on streets against Shehbaz Sharif govt
